Acadia Pharmaceuticals (ACAD) Equity Average (2011 - 2026)

Acadia Pharmaceuticals has reported Equity Average for 16 years, with the latest figure at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 65.25% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (up 65.25% YoY), and the FY2025 full-year result was $980.1 million, up 68.32% from the prior year.
• Equity Average for Q1 2026 stood at $1.2 billion, up from $1.1 billion in the prior quarter.
• The five-year high for Equity Average was $1.2 billion in Q1 2026, with the low at $379.0 million in Q3 2023.
• Average Equity Average over 5 years is $599.2 million, with a median of $490.4 million recorded in 2024.
• Year-over-year, Equity Average fell 25.43% in 2022 and jumped 67.23% in 2025.
• Tracing ACAD's Equity Average over 5 years: stood at $413.0 million in 2022, then fell by 3.89% to $397.0 million in 2023, then soared by 65.0% to $655.0 million in 2024, then soared by 63.72% to $1.1 billion in 2025, then gained by 15.42% to $1.2 billion in 2026.
• The last three Equity Average figures came in at $1.2 billion (Q1 2026), $1.1 billion (Q4 2025), and $869.8 million (Q3 2025), per Business Quant data.

Peer Comparison